AIM ImmunoTech has been granted a patent for a method to prevent or reduce antigenic drift and viral reassortment in influenza viruses. The method involves determining if a host animal or human has been exposed to avian influenza and administering a-interferon to reduce symptoms. The a-interferon includes seven species and can be administered through various routes. GlobalData’s report on AIM ImmunoTech gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AIM ImmunoTech, Peptide pharmacophores was a key innovation area identified from patents. AIM ImmunoTech's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Method for reducing antigenic drift or viral reassortment in humans
A recently granted patent (Publication Number: US11642396B2) describes a method for reducing antigenic drift or viral reassortment in humans who have been exposed to or infected by avian influenza viruses. The method involves administering a-interferon to the exposed or infected individuals. The a-interferon used in this method consists of seven species: a2, a4, a7, a8, a10, a16, and a17. The a-interferon can be administered intravenously, subcutaneously, intramuscularly, or intranasally.
The patent claims specify that the avian influenza virus can be NA-292R H7N9, NA-292K H7N9, or a combination of both. Additionally, the avian influenza virus can also be a combination of NA-292R H7N9, NA-292K H7N9, and at least one more avian influenza virus.
The a-interferon species used in the method are purified as a mixture of at least seven species produced by human white blood cells. The concentration of a-interferon administered is within the range of 1,000 IU/ml to 10,000 IU/ml. The dosage of a-interferon per administration can range from 1,000 IU to 10,000,000 IU.
This patent presents a method for reducing antigenic drift or viral reassortment in humans exposed to or infected by avian influenza viruses. By administering a-interferon, specifically a mixture of seven species, the method aims to prevent or minimize the genetic changes in the virus that can lead to increased virulence or resistance to existing treatments. The use of a-interferon as a therapeutic agent has been studied extensively, and this patent provides a specific combination of a-interferon species for this purpose.
The patent's claims also highlight the specific avian influenza viruses that can be targeted with this method, including NA-292R H7N9, NA-292K H7N9, and combinations thereof. This suggests that the method can be applied to different strains or combinations of avian influenza viruses, potentially broadening its applicability.
The concentration and dosage range specified in the claims provide guidance for the administration of a-interferon in this method. These ranges can help inform future research and clinical trials to determine the optimal dosage for achieving the desired reduction in antigenic drift or viral reassortment.
Overall, this granted patent presents a method for reducing antigenic drift or viral reassortment in humans exposed to or infected by avian influenza viruses using a-interferon. The specific combination of a-interferon species, the targeted avian influenza viruses, and the dosage ranges outlined in the claims provide valuable information for further research and potential therapeutic applications.
To know more about GlobalData’s detailed insights on AIM ImmunoTech, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
